Oxatomide

DB12877

small molecule approved investigational

Deskripsi

Oxatomide has been used in trials studying the treatment of Muscular Dystrophy, Duchenne.

Struktur Molekul 2D

Berat 426.564
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with food.

Interaksi Obat

402 Data
Ivabradine Ivabradine may increase the QTc-prolonging activities of Oxatomide.
Benzylpenicilloyl polylysine Oxatomide may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.
Betahistine The therapeutic efficacy of Betahistine can be decreased when used in combination with Oxatomide.
Amphetamine Amphetamine may decrease the sedative activities of Oxatomide.
Phentermine Phentermine may decrease the sedative activities of Oxatomide.
Pseudoephedrine Pseudoephedrine may decrease the sedative activities of Oxatomide.
Benzphetamine Benzphetamine may decrease the sedative activities of Oxatomide.
Diethylpropion Diethylpropion may decrease the sedative activities of Oxatomide.
Lisdexamfetamine Lisdexamfetamine may decrease the sedative activities of Oxatomide.
Mephentermine Mephentermine may decrease the sedative activities of Oxatomide.
MMDA MMDA may decrease the sedative activities of Oxatomide.
Midomafetamine Midomafetamine may decrease the sedative activities of Oxatomide.
2,5-Dimethoxy-4-ethylamphetamine 2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Oxatomide.
4-Bromo-2,5-dimethoxyamphetamine 4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Oxatomide.
Tenamfetamine Tenamfetamine may decrease the sedative activities of Oxatomide.
Chlorphentermine Chlorphentermine may decrease the sedative activities of Oxatomide.
Methylenedioxyethamphetamine Methylenedioxyethamphetamine may decrease the sedative activities of Oxatomide.
Dextroamphetamine Dextroamphetamine may decrease the sedative activities of Oxatomide.
Metamfetamine Metamfetamine may decrease the sedative activities of Oxatomide.
Iofetamine I-123 Iofetamine I-123 may decrease the sedative activities of Oxatomide.
Ritobegron Ritobegron may decrease the sedative activities of Oxatomide.
Mephedrone Mephedrone may decrease the sedative activities of Oxatomide.
Methoxyphenamine Methoxyphenamine may decrease the sedative activities of Oxatomide.
Gepefrine Gepefrine may decrease the sedative activities of Oxatomide.
2,5-Dimethoxy-4-ethylthioamphetamine 2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Oxatomide.
Phendimetrazine Phendimetrazine may decrease the sedative activities of Oxatomide.
Dofetilide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Dofetilide.
Citalopram The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Citalopram.
Anagrelide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Anagrelide.
Disopyramide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Disopyramide.
Clemastine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Clemastine.
Ibutilide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Ibutilide.
Valproic acid The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Valproic acid.
Terfenadine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Terfenadine.
Grepafloxacin The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Grepafloxacin.
Quinine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Quinine.
Sotalol The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Sotalol.
Erlotinib The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Erlotinib.
Toremifene The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Toremifene.
Cisapride The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Cisapride.
Imatinib The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Imatinib.
Astemizole The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Astemizole.
Thioridazine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Thioridazine.
Trovafloxacin The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Trovafloxacin.
Mifepristone The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Mifepristone.
Cocaine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Cocaine.
Quinidine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Quinidine.
Procainamide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Procainamide.
Pimozide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Pimozide.
Amiodarone The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Amiodarone.
Arsenic trioxide The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Arsenic trioxide.
Escitalopram The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Escitalopram.
Domperidone The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Domperidone.
Sparfloxacin The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Sparfloxacin.
Halofantrine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Halofantrine.
Bepridil The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Bepridil.
Paliperidone The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Paliperidone.
Lithium cation The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Lithium cation.
Temafloxacin The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Temafloxacin.
Zuclopenthixol The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Zuclopenthixol.
Tetrabenazine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Tetrabenazine.
Dronedarone The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Dronedarone.
Nilotinib The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Nilotinib.
Iloperidone The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Iloperidone.
Vandetanib The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Vandetanib.
Romidepsin The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Romidepsin.
Asenapine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Asenapine.
Artemether The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Lumefantrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Vemurafenib.
Eliglustat The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Eliglustat.
Ribociclib The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Oxatomide.
Glasdegib The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Glasdegib.
Deutetrabenazine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Deutetrabenazine.
Macimorelin The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Macimorelin.
Terodiline The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Terodiline.
Leuprolide The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Oxatomide.
Goserelin The risk or severity of QTc prolongation can be increased when Goserelin is combined with Oxatomide.
Erythromycin The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Oxatomide.
Azithromycin The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Oxatomide.
Moxifloxacin The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxatomide.
Ranolazine The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Oxatomide.
Sulfisoxazole The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Oxatomide.
Amitriptyline The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Oxatomide.
Methadone The risk or severity of QTc prolongation can be increased when Methadone is combined with Oxatomide.
Diltiazem The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Oxatomide.
Clozapine The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Clozapine.
Sulpiride The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Oxatomide.
Nimodipine The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Oxatomide.
Promazine The risk or severity of QTc prolongation can be increased when Promazine is combined with Oxatomide.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Oxatomide.
Droperidol The risk or severity of QTc prolongation can be increased when Droperidol is combined with Oxatomide.
Imipramine The risk or severity of QTc prolongation can be increased when Imipramine is combined with Oxatomide.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Oxatomide.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Oxatomide.
Ciprofloxacin The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Oxatomide.
Fluorouracil The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Oxatomide.
Perflutren The risk or severity of QTc prolongation can be increased when Perflutren is combined with Oxatomide.
Cinnarizine The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Oxatomide.
Atropine The risk or severity of QTc prolongation can be increased when Atropine is combined with Oxatomide.

Target Protein

Histamine H1 receptor HRH1

Referensi & Sumber

Contoh Produk & Brand

Produk: 0 • International brands: 2
International Brands
  • Celtect
  • Tinset

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul